Skip to main content

Table 4 Differences in mean intraocular pressure between visits during the second crossover period

From: Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study

Per-protocol population

Treatment group/time-point

Month 3-month 5

Month 5-month 6

n

 

mm Hg ± SD

P value*

mm Hg ± SD

P value*

 

Dorz/brim/tim 8 am

+2.0 ± 0.2

0.004

+1.0 ± 0.5

0.035

30

Dorz/brim/tim 10 am

-0.3 ± 0.4

0.036

+0.5 ± 0.1

0.031

Bim/tim 8 am

+0.1 ± 0.4

0.007

-1.0 ± 0.4

0.003

26

Bim/tim 10 am

+0.3 ± 0.1

0.031

-0.4 ± 0.5

0.015

  1. *Student t test.
  2. Bim/tim, bimatoprost 0.03% and timolol maleate 0.5%; dorz/brim/tim, dorzolamide 2%, brimonidine 0.2%, and timolol maleate 0.5%; SD, standard deviation.
Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us